Robbins LLP is Investigating Allegations that Unicycive Therapeutics, Inc. Failed to Properly Inspect its Third-Party Vendor's Manufacturing Facility to Ensure it Resolved the FDA's Previously Noted Deficiencies
Shareholder rights firm Robbins LLP is soliciting investors for a securities class action against Unicycive Therapeutics (NASDAQ: UNCY) covering purchasers between December 29, 2025 and June 29, 2026, with a November 2, 2026 lead plaintiff deadline. The complaint alleges Unicycive failed to inspect its third-party manufacturing vendor's facility before resubmitting the OLC NDA, and that the FDA's June 2026 Complete Response Letter cited the same third-party manufacturing deficiencies as the June 2025 CRL.
Key figures
- Class period
- December 29, 2025 to June 29, 2026
- Stock drop pct
- 39.1%
- Post drop close price
- 4.69
- Lead plaintiff deadline
- November 2, 2026
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.